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Abstract
Although silent atrial fibrillation (AF) accounts for a significant proportion of patients with AF, asymptomatic patients have been excluded 
from AF ablation trials. This population presents unique challenges to disease management. Recent evidence suggests that patients with 
asymptomatic AF may have a different risk profile and even worse long-term outcomes compared to patients with symptomatic AF. For the 
same reasons they might be more prone to side-effects of antiarrhythmic drugs, including pro-arrhythmias. 
The poor correlation between symptoms and AF demonstrated in several studies should caution physicians against making clinical 
decisions depending on symptoms. Although current guidelines recommend AF ablation only in patients with symptoms, more attention 
should be paid to the AF burden and a rhythm control strategy has the potential to improve morbidity and mortality in AF patients. However, 
limited data exist regarding the use of catheter ablation for asymptomatic AF patients.
As ablation techniques have improved, AF ablation has become more widespread and complication rate decreased. As a result, referrals 
of asymptomatic patients for catheter ablation of AF are on the rise. In this review we discuss the many unresolved questions concerning the 
role of the ablative approach in asymptomatic patients with AF. 
Introduction
Atrial fibrillation (AF) is the most common cardiac rhythm 
disturbance seen in clinical practice1 and it is associated with 
an increased long-term risk of stroke, heart failure and all cause 
mortality.2-4 Appropriate management of AF-patients has been 
engaging clinicians for many years; although there are clear 
guidelines for the acute management of symptomatic AF,5the best 
long-term approach for patients with a first or recurrent AF is still 
debated with regard to quality of life, risk of rehospitalization, and 
possible disabling complications such as thromboembolic stroke, 
major bleeding and death.
The mainstay of treatment for AF has traditionally been 
pharmacological; however, the limited efficacy and proarrhythmic 
risks of anti-arrhythmic drugs (AAD) have led to the development 
of non-pharmacologic therapeutic approaches.6 Two arrhythmia 
strategies for AF treatment are currently offered to patients: rate 
control and rhythm control. A few randomized trials comparing 
outcomes of rhythm vs rate-control strategies have been published. In 
particular, the AFFIRM, RACE and AF-CHF trials7-9 demonstrated 
no differences in terms of morbidity and mortality when comparing 
rate versus rhythm control strategies in patients with AF. However, 
when data from these trials are analyzed according to patient’s actual 
rhythm, the benefit of sinus rhythm over AF becomes apparent, 
reflecting the ineffectiveness of the rhythm control methods used.10 
The introduction of new rhythm-control strategies with higher 
efficacy and less adverse effects might produce superior long-term 
results to either rate control or rhythm control using antiarrhythmic 
drugs.
A number of controlled, randomized clinical trials have consistently 
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shown that catheter ablation is superior to antiarrhythmic 
pharmacological treatment in maintaining sinus rhythm among 
patients with drug-refractory AF.11-17 In particular, most of the 
published trials have reported a considerable success rate in patients 
with paroxysmal AF and without marked underlying cardiac disease 
with a relatively safe risk profile.18-21 Currently, patients selected 
for AF catheter ablation represent a highly symptomatic subgroup 
within the total AF population and guidelines recommend catheter 
ablation in those patients with a goal of improving patient’s quality 
of life. However, AF is often asymptomatic and only discovered 
by chance or when stroke has already occurred. Hence, there is a 
need to improve outcomes in patients with silent AF. Beyond oral 
anticoagulation (OAC), a rhythm control strategy is potentially 
beneficial to these patients.  
Symptoms and Quality of life in AF Patients: Some Answers 
but Even More Questions. 
Although AF is responsible for a variety of symptoms, it is estimated 
that one third of patients with AF report no overt symptoms and 
are unaware of their arrhythmic condition: a condition referred to 
as silent or asymptomatic AF. The prevalence of asymptomatic 
AF varies considerably among the different studies, depending on 
the enrolled population or the methods in which the rhythm is 
documented [Table 1]. Studies with transtelephonic or implantable 
monitoring devices have reported asymptomatic AF in up to 50% 
of evaluated patients,42,43 even in the most symptomatic ones.43,44 
As AF ablation has become more widespread, there is a number of 
reasons to consider this non-pharmacological approach in the overall 
management of patients with silent AF.
AF-Related Symptoms: Relying on the Untrustable
Symptoms are a major reason for which patients with AF 
seek medical attention but there are many unresolved questions 
concerning the relation between symptoms and AF. As known, there 
is a weak association between symptoms and the actual rhythm; AF 
can present in a variety of clinical scenarios, symptoms are often very 
subjective and may not be specific for AF because other cardiovascular 
conditions and risk factors for AF may cause similar symptoms and 
predispose the patient to the AF itself. Furthermore, given the age-
related prevalence of both AF and cardiovascular disorders (greater 
in older patients), it is inherently difficult to evaluate AF-related 
symptoms in a vast proportion of AF patients. 
 There is currently no reliable method to precisely identify AF-
related symptoms and no standardized assessment of symptoms 
or functional status has been accepted as the gold standard in AF 
patients. Regardless of their level of symptoms, patients, are not 
consistently able to accurately report the presence or absence of AF 
episodes45 and the relationship between symptoms and the onset of 
the arrhythmia is not always obvious. Thus, the simple awareness of 
symptoms is not a good discriminator of the presence or absence of 
this arrhythmia. All symptoms without a clearly determined non-AF 
cause should be classified as AF-related symptoms but symptoms 
are difficult to measure objectively and many AF patients have 
some vague nonspecific discomfort such as dizziness or fatigue. An 
important way to overcome this limitation is to analyze symptoms 
according to rhythm status: AF-related symptoms should be closely 
related to the underlying rhythm, disappearing after restoration of 
sinus rhythm. This is easier to note for palpitations compared to 
Table 1: Published studies reporting the prevalence of asymptomatic atrial 
fibrillation
Study (Reference) Population Follow-up 
(months)
Silent AF (%)
Defaye et al. 1996 
(22) 
617 with DDD PMK 1 • 58%
• 21% (newly 
developed AF)
Kerr et al. 1996 (23) 674 with AF 12 21% 
Lévy et al. 1999 (24) 756 with AF 12 11.4%
Page et al. 2003 (25) 1380 in sinus rhythm with 
a history of AF/AFlutter 
receiving placebo or 
azimilide
9 • Placebo group: 18%
• Azimilide group: 
13%
Flaker et al. 2005 
(26) 
4060 randomized to either 
rhythm or rate control
60 12% at baseline
Hindricks et al. 2005 
(27) 
114 with highly-symptomatic 
drug-refractory AF 
undergoing PVI
12 • Before ablation: 5%
• After ablation: 
→ Immediately: 22%
→ 3-mo: 38%
→ 6-mo: 37%
→ 12-mo: 36%
Neumann et al. 2006 
(28)
80 with paroxysmal AF 
undergoing PVI
12 • Symptomatic: 36.3%
• Asymptomatic: 
13.7%
• Mixed: 7.5%
Wasamreddy et al. 
2006 (29) 
19 with highly-symptomatic 
drug-refractory AF 
undergoing catheter ablation
6 82.4% of AF episodes
Janse et al. 2007 (30) 41 undergoing PVI 5 • Before ablation: 35% 
of AF episodes
• After ablation: 65% 
of AF episodes
Pontoppidan et al. 
2009 (31) 
149 with paroxysmal/
persistent AF undergoing PVI
12 • Symptomatic: 14.6%
• Asymptomatic: 
15.5%
• Mixed: 2.9%
Hickey et al. 2010 
(32) 
54 with a history of systolic 
heart failure and/or 
hypertension
0,5 2%
Cabrera et al. 2011 
(33) 
585 undergoing PMK 
implantation
66 27% of patients with 
new episodes of AF 
detected by 12-lead 
ECG or by device 
interrogation
Healey et al. 2012 
(34) 
2580 patients ≥ 65 years 
with ICD or PMK
3 10.1%
Winkle et al. 2012 
(35) 
203 patients off anti-
arrhythmic drugs, clinically 
free of AF after catheter 
ablation
12 • 4.3% on 7-day Holter 
monitoring
• 23.5% on PMK 
interrogation
Sobocinski et al. 
2012 (36) 
249 who had suffered an 
ischemic stroke/transient 
ischemic attack
1 6.8% of patients 
diagnosed with AF
→ Symptomatic 
episodes: 22%
→ Asymptomatic 
episodes: 78% 
Samol et al. 2013 
(37)
132 with cardiovascular risk 
factors
- 5.3%
Potpara et al. 2013 
(38) 
1100 with first diagnosed AF 120 13.3%
Engdahl et al. 2013 
(39)
848 75-year old patients - • 1.2% on 12-lead 
ECG recording
• 7.4% on hand-held 
ECG event recording
Verma et al. 2013 
(40)
50 with symptomatic AF 
undergoing PVI
21 56% of AF episodes
Tondo et al. 2013 (41) 143 implanted with a 
continuous cardiac monitor 
following PVI
14 46%
AF= atrial fibrillation; PMK= pacemaker; PVI= pulmonary vein isolation; ICD= implantable 
cardioverter defibrillator.
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Society Consensus Document for standardized reporting of clinical 
trial outcomes.47  Despite such limitations, the presence of symptoms 
still represent an important issue in the management of AF patients 
and few minimally symptomatic or asymptomatic patients are 
referred for ablative therapy. The poor correlation between symptoms 
and AF demonstrated in several studies should caution physicians 
against making clinical decisions depending on symptoms. 
Revisiting Quality of Life in AF Patients: Even in Asymptomatic 
Ones.
Patients with AF have a considerably impaired quality of life 
(QoL) that is independent on the severity of the disease. Restoration 
and maintenance of sinus rhythm is associated with a significant 
increase in QoL.48-50 Rather surprisingly, several aspects of QoL may 
be reduced in AF patients even in the absence of overt AF-related 
symptoms.42,51 Although this condition might be related in part to 
the knowledge that they have a cardiac illness, patients remaining 
in AF often continue to experience poor exercise tolerance which 
is difficult to recognize as an AF-related symptom. Furthermore, a 
reduced QoL in patient with silent AF may also be related to the 
use of drugs after AF is discovered. The negative effect on QoL with 
AADs or with OAC therapy is no surprising; in fact, many patients 
request an ablation procedure merely to “get off drugs”. Moreover, it 
is very likely that in many cases the so called “asymptomatic” patients 
have vague nonspecific symptoms such as dizziness or fatigue not 
clearly attributable to AF.  
Although the improvement in QoL on restoration and maintenance 
of SR is more evident in highly symptomatic AF patients,52  several 
aspect of overall lifestyle might be improved even in the absence of 
symptoms of the arrhythmia. Therefore, even asymptomatic patients 
with AF have the potential to show significant benefits in both non-
specific symptoms and overall lifestyle with a rhythm control strategy, 
also in case of a failed ablation procedure.53
Management of AF Patients: Beyond Symptoms Improve-
ment.
The results of the RACE and AFFIRM trials can not be easily 
compared to all asymptomatic patients with AF. These studies 
enrolled predominantly older patients (> 70 years), most of whom 
had persistent AF and heart disease, and follow-up extended over 
just a few years. Those patients are probably older and with more 
severe underlying heart disease as compared to asymptomatic AF 
patients recognized by chance during a clinical evaluation. Thus, the 
trial data do not necessarily apply to younger patients without heart 
disease or to patients who are prone to deteriorate over time if left 
in AF. As AF ablation has become a more mainstream therapy, the 
clinical population has broadened providing us with greater insight 
into the potential efficacy. 
Prevention of Heart Failure
It was long appreciated that long-term AF may also lead to 
tachycardia-induced cardiomyopathy with symptoms and signs of 
heart failure (HF).54 Rapid ventricular rate, loss of atrioventricular 
synchrony and irregularity of RR intervals are the primary mechanisms 
that adversely affect ventricular function and hemodynamic status.55 
Prompt sinus rhythm restoration may improve left ventricular systolic 
function and reverse tachycardiomyopathy. 
It is likely that the benefits of sinus rhythm are counterbalanced by 
toxicity of AADs combined with their limited efficacy, particularly 
other symptoms (eg. exertional dyspnea); however, the intensity of 
palpitations during AF recurrences might gradually decrease until 
becoming subclinical. 
The lack of a reliable instrument to assess AF-related symptoms 
prompted an expert consensus panel to propose an AF classification 
to compare symptoms across trials and in clinical practice.46  Due 
to the above mentioned limitations, symptoms are recommended 
as secondary outcome parameters in AF trials and the EHRA 
classification of AF symptoms does not clearly distinguish between 
symptoms caused by AF or the underlying heart disease.45 Of note, 
the end point “elimination of any atrial arrhythmia irrespective of 
symptoms” has been recommended by the Heart Rhythm Society/
European Heart Rhythm Association/European Cardiac Arrhythmia 
Table 2: Published studies evaluating the risk of stroke in AF patients with 
or without symptoms.
                                                                                                                          Risk of stroke in 
asymptomatic AF
Glotzer et al. 
2003 (61)
312 with PMK that 
monitor AHRE 
27 • 51.3% of cases with AHRE
• hazard ratio AHRE vs. non-AHRE for 
death or non-fatal risk of stroke: 2.79
Glotzer et al. 
2009 (62)
2486 with ≥ stroke risk 
factors receiving PMK or 
ICD that monitor AT/AF 
burden*
16 Annualized risk:
• Group zero: 1.1%
• Group low: 1.1%
• Group high: 2.4%
Healey et al. 
2012 (34) 
2580 ≥65 years 
undergoing PMK or ICD 
implantation
29 Attributable risk of stroke or systemic 
embolism associated with subclinical 
AF: 13%
                                                                                                                 Risk of stroke in 
asymptomatic vs. symptomatic AF       
Flaker et al. 2005 
(26)
4060 randomized to 
either rhythm or rate 
control
60 • Stroke: p=0.43
• Combined end-point (death, 
disabling stroke or anoxic 
encephalopathy, major central 
nervous system haemorrhage, 
cardiac arrest): p=0.34
Cullinane et al. 
1998 (63) 
111 undergoing 
transcranial Doppler 
recordings (1h) for 
asymptomatic embolic 
signals detection
- Embolic signals during recordings: 
p=0.84
Potpara et al. 
2013 (38) 
1100 120 Higher risk in asymptomatic: 
p=0.013
                                                                                                                     Incidence of AF among 
patients with stroke
Wolf et al. 1983 
(64)
5184 (Framingham 
study)
360 • 501 cases of stroke
• 59 cases of stroke in the presence 
of AF
Wolf et al. 1991 
(65)
5070 (Framingham 
study)
408 • 572 cases of strokes
• 114 cases of embolic stokes
• 311 newly diagnosed AF
Lin et al. 1995 
(66)
5070 (Framingham 
study)
456 • 656 cases of stroke
• 115 cases of strokes in the 
presence of AF
• 89 cases of stroke with previously 
documented episodes of AF
• 21 cases had AF discovered for the 
first time on admission for the stroke
• 5 cases developed AF after 
admission
Sobocinski et al. 
2012 (36)
249 stroke patients 1 17 (6.8%) newly diagnosed cases of 
silent AF
AF= atrial fibrillation; AHRE = atrial high rate events; AT = atrial tachycardia; PMK= pacemaker; 
ICD= implantable cardioverter defibrillator. 
* AT/AF burden: the longest total AT/AF duration on any given day during the prior 30-day period 
(group zero: noAT/AFevents; group low: <5.5 hours; group high: >5.5 hours)
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in HF patients. On the other hand, AF ablation has been shown 
to reverse AF-related cardiomyopathy,55-57 and to prevent 
cardiomyopathy development in earlier stages of AF. The potential 
benefits of restoring and maintaining sinus rhythm, including a lower 
risk of heart failure and a better quality of life may partially explain 
why recent surveys demonstrated that cardiologists tend to offer a 
rhythm-control strategy in the majority of patients with primary 
diagnosis of AF.58-59 Given the potential adverse effects from long-
term anti-arrhythmic therapy in HF patients, a non-pharmacologic 
approach with catheter ablation might be a promising strategy for 
this subset of patients.60
Role of AF Ablation. Soft and Hard End-Points Matter
Silent AF is likely to be associated with morbidity and mortality 
rates not inferior to symptomatic AF,26,34,38therefore, elimination of 
AF has the potential to reduce that risk. It is not uncommon that 
AF is found incidentally on admission for stroke and a significant 
proportion of patients presenting with stroke has AF that was not 
previously recognized (Table 2). However, maintaining SR with 
AADs might be ineffective due to the potential side effects of 
pharmacological therapy that may in fact increase mortality. On the 
other hand, AF ablation is highly effective in maintaining freedom 
from AF in the majority of patients without the need for AADs, 
so beyond symptomatic relief the impact of AF ablation on hard 
end points such as stroke, cardiovascular events or death needs to be 
clarified. 
Published studies have demonstrated that asymptomatic patients 
are more frequently males with non-paroxysmal AF of lower 
ventricular rates.38  But other studies demonstrated that factors 
associated to asymptomatic episodes include female sex, paroxysmal 
AF, younger age and negative emotions.67-69 It is therefore difficult 
to identify a clinical profile of the patient who would be more or 
less likely to manifest symptoms. Recently, in a large study of first-
diagnosed non-valvular AF patients, Potpara et al.38 showed that 
patients with CHA2DS2–VASc = 0 had a 2-fold greater risk of 
asymptomatic presentation of incident AF compared to those with 
CHA2DS2–VASc score >0. Of note, this study demonstrated in a ‘real-
world’ setting, that although patients with asymptomatic AF have a 
more favorable baseline profile, they have a greater risk of progression 
to permanent AF and a trend towards an increased risk of ischemic 
stroke despite OAC. As reported by Potpara and colleagues in their 
paper: ”these findings raise the question of whether AF ablation (with 
recent improvements in AF ablation techniques) should be the first-
line treatment for asymptomatic AF patients, since a non-invasive 
rhythm control could be less efficient in these patients”. 
The reduced mortality with sinus rhythm has also been 
demonstrated virtually in every study that has monitored this end 
point and there is emerging evidence that sinus rhythm restoration 
following AF ablation can provide clinical and prognostic benefits. In 
an international multicentre registry, Hunter et al.70 demonstrated in 
1273 patients that the ablation strategy is associated with lower rates 
of stroke and death compared to AF-patients treated medically. Rates 
of stroke and death were significantly lower in ablated patients (both 
0.5% per patient-year) compared to those treated medically in the 
Euro Heart Survey. This observation is in line with the results from 
other smaller registries.71-75 Furthermore, Winkle et al76have recently 
demonstrated that patients with prior stroke, who undergo successful 
AF ablation, have a low incidence of subsequent thromboembolic 
events and most of those patients may be able to discontinue OAC. 
The consistency of these findings suggests that, compared with 
pharmacological treatment, restoration of sinus rhythm by catheter 
ablation of AF is associated with lower rates of stroke and death. 
Prognostic benefit of AF ablation is difficult to demonstrate due to 
the low-risk cohorts that have been selected for catheter ablation until 
recently and there are no randomized controlled trials examining this 
problem. Short-term studies might not have a sufficient statistical 
power to detect an effect on morbidity and mortality; this will be 
possible in long-term large trials enrolling patients at relatively 
high risk for AF-related complications. The multicentric Catheter 
Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation 
(CABANA) trial77 is prospectively investigating the long term effect 
of catheter ablation on mortality compared to medical therapy. This 
trial aims to randomize worldwide 3000 high-risk AF patients (≥65 
yo or <65 with >1 risk factor for stroke) to a strategy of catheter 
ablation versus pharmacologic therapy (Rate or Rhythm Control). If 
this study show that AF ablation is superior to current state-of-the-
art therapy with either rate control or rhythm control drugs, this will 
have massive implications even in patients with asymptomatic AF.
One additional issue deserves our attention. Patients with 
left ventricular dysfunction and suspected tachycardia-induced 
cardiomyopathy secondary to AF have been demonstrated to 
significantly benefit from atrioventricular-node ablation with 
pacemaker implantation, and biventricular pacing (CRT) has 
been shown to be more effective than right ventricular pacing.78-80 
The “Ablate and Pace” strategy is usually considered for patients 
with incessant and drug-resistant AF; however, the PABA-CHF 
trial60 demonstrated the superiority of AF ablation as compared 
to atrioventricular-node ablation with biventricular pacing in HF 
patients. Of note, this study enrolled patients from 2002 to 2006 
and in the meantime CRT technology has significantly evolved. 
In particular, we have moved from unipolar left ventricular leads 
to the currently available quadripolar technology that has been 
demonstrated to improve outcomes in CRT patients.81-82  The 
“Ablate and Pace” strategy with multielectrode left ventricular 
leads has a higher likelihood of improvement after CRT; however, 
the additional benefit of the quadripolar technology in patients 
undergoing atrioventricular-node ablation remains to be proven.
Rhythm Control and Progression of AF: the Sooner the Better?
Older patients and those at the highest risk for stroke might 
benefit from an early ablative approach therapy when diagnosed 
with AF and may be the best candidates to screen for silent AF. 
However, the benefit on long-term mortality after sinus rhythm 
restoration in asymptomatic AF patients is not limited to older 
patients at high risk of stroke. Death and AF-related complications 
appear higher during the first months after the initial manifestation 
of AF.4 Moreover, complication rates have decreased over the years in 
AF trials.83 In younger AF patients with few comorbidities, there is 
some evidence that restoring sinus rhythm might improve long term 
survival; Wazni et al.11 demonstrated that catheter ablation as first-
line therapy in patients with new onset AF results in better outcome 
at one year compared to treatment with AAD, raising the possibility 
of using catheter ablation in AF management earlier than previously 
envisaged. 
The natural history of AF recognizes different stages. In early 
stages, nonsustained episodes trigger-driven from pulmonary veins 
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ablation in asymptomatic AF patients using data taken from a large 
Italian registry (IRON-AF). Although the study was limited by its 
retrospective design, it represents the first analysis of the effect of 
catheter ablation in patients with subclinical AF so far reported.89 
In this ‘real-world’ cohort, 545 consecutive patients referred for 
AF ablation guided by the NavX system (St. Jude Medical Inc., St. 
Paul, MN, USA) were prospectively enrolled.90 Of these patients, 
54 were determined to have subclinical AF; the control group was 
the remaining 486 patients who had symptoms. Analyses of efficacy, 
safety and outcomes of AF ablation revealed that the procedure in 
asymptomatic patients was safe and effective and performed as well 
as ablation in their symptomatic counterpart. 
An important point of interest that emerged from this multicenter 
registry is represented by the relatively high number of asymptomatic 
patients undergoing “off-label” AF ablation. Reasons to ablate 
asymptomatic patients include young age, prevention of embolism 
and avoidance of cardiomyopathy, raising the possibility that this 
might reduce mortality rate. Another potential explanation for this 
finding is that one of the goals of AF ablation in an asymptomatic 
population is to eliminate the need for long-term anticoagulant 
and AAD therapy. Since this study was performed in 16 centers, 
the results are representative of a broad general experience with AF 
ablation; therefore, it is likely that referrals of asymptomatic patients 
for catheter ablation of AF are on the rise.
Assessment of Ablation Success in Patients with Silent AF.
 Monitoring for arrhythmia recurrences after silent AF ablation 
is a key component of postablation follow-up not only to assess its 
real overall efficacy but also to tailor the therapeutic strategy for the 
individual patient. Systematic, standardized ECG monitoring has 
been shown to be of value in asymptomatic patients; however, it 
is recognized that the more intensively a patient is monitored and 
the longer the period of monitoring, the greater the likelihood of 
detecting AF recurrences.
Several methods of follow-up are available that range from 
1 to 7 day Holter monitoring to implantable monitors that can 
provide extended periods of continuous monitoring. While external 
continuous monitoring systems provide limited temporal assessment, 
the implantation of a leadless cardiac monitor represents the 
gold standard for long-term AF surveillance, facilitating reliable 
assessment of  asymptomatic AF episodes.91-92 Since AF recurrences 
may occur during the first years after ablation,93 the use of these 
tools for objective AF documentation might represent an optimal 
postablation monitoring strategy. Furthermore, even if currently 
available devices require a minimally invasive implant technique, this 
technology is evolving and in the near future small injectable devices 
will be available. Considering the technological improvements and 
the battery longevity (up to 6 years), these devices might be used as 
an objective and cost-effective postoperative assessment.
Safety Concerns of AF Ablation in Asymptomatic Patients.
 In evaluating any treatment, one must balance the rewards and the 
risks. Asymptomatic patients have largely been excluded from AF 
ablation trials because of concerns regarding safety and efficacy of 
catheter ablation. Controversies exist with regard to the procedural 
safety of AF ablation; reports from high volume centers claim very 
low complication rates even though several major adverse events in 
patients undergoing catheter ablation for AF have been reported 
are the rule. Overtime, atrial remodeling starts to occur and the new 
electro-anatomical  substrate contribute to the development of longer 
arrhythmic episodes. Prompt restoration of sinus rhythm prevents 
long term left atrial structural remodeling that is associated with an 
increased risk of thromboembolism.84 Therefore, AF ablation at earlier 
stages of the disease is more likely to succeed and has the potential 
to slow the progression of AF.85-86   Bunch et al.87 demonstrated on 
4335 patients undergoing AF ablation that increasing time between 
first diagnosis of atrial fibrillation and treatment adversely affects 
long term outcomes. Additionally, the authors reported that AF-
related outcomes such as heart failure and death tended to worsen 
with delays in rhythm management. These data in aggregate suggest 
that AF disease progression may be favorably impacted with early 
catheter ablation; if the intervention is driven only by symptoms, we 
might face in the operating room with more advanced stages of AF, 
requiring an extensive substrate modification, with a lower success 
rate and an increased risk of procedural complications.
Of note, a symptom-guided approach might be misleading because 
AF often worsens insidiously in mild symptomatic patients. Kawara 
et al.88 retrospectively analyzed AF symptoms in patients with and 
without subsequent permanent atrial fibrillation. Interestingly, they 
reported that permanent AF often develops in patients with mild 
rather than severe symptoms. Given the progression of AF and 
the associated atrial remodeling, treatment of AF at an early stage 
may mitigate the progression of AF from a treatable problem to a 
condition refractory to all therapeutic interventions.
The Importance of the Patient’s Perspective
The aim of all medical treatments is to improve outcomes for 
patients but what does “improve outcomes” mean? Usually, there 
are many outcomes to a treatment: symptoms relief, reduced risk of 
death and disability, complications, economic impact and so on. How 
do we weight these different aspects of outcome to determine which 
treatment is preferred?
Clinicians continue recognizing the importance of patients’ 
perspective in the assessment of health care treatments and the 
symptom burden associated with AF is a major consideration in the 
overall management of the arrhythmia. Symptoms are the major 
motivation for undergoing catheter ablation in patients with AF; 
however, does all therapies in AF have the sole indication of symptom 
relief ? Of course the answer is no. Symptomatic improvement 
has been frequently utilized in the evaluation of any therapeutic 
approach in AF patients; however, it has a low value in the clinical 
and prognostic care of patients. 
The elusive relation between symptoms and arrhythmia recurrences 
suggests that symptoms may at times not be related to AF but rather 
an expression of other processes. Furthermore, it is well known that 
reliance on perception of AF by patients after AF ablation results in 
an underestimation of recurrence of the arrhythmia.31,40 This makes 
symptoms and AF-related quality of life a potentially unreliable 
outcome parameter. The main topic is that AF is responsible for an 
increased risk of stroke and death, and elimination of AF normalizes 
that risk. More attention should be paid to the AF burden but less to 
the clinical symptoms, and treatment should be delivered accordingly.
The Experience of AF Ablation in Patients with Asymptomatic AF: 
the IRON AF Study.
 We have recently evaluated the safety and the efficacy of catheter 
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Despite increasing experience, procedural risks of ablation are 
diminishing but are not insignificant.94 Largely for these reasons, 
current guidelines recommend catheter ablation in patients with 
AF-related symptoms. The major benefit of catheter ablation for AF 
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in mortality or stroke. This prompt an important question: is AF a 
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Conclusions:
Asymptomatic AF is common and could lead to devastating 
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